Huntsman and Olin merger faces investor skepticism in chemicals sector

Traders Union
All News
Financial News
Huntsman-Olin merger skepticism

Highlights

Huntsman shares fell 17% and Olin shares dropped 6% on Tuesday after announcing their merger, erasing nearly $650 million in combined market value.
The all-stock merger aims for $400 million in annual cost savings, totaling about $3 billion, but investors doubt these synergies offset integration risks.
The combined enterprise value of $10 billion is less than a single year's revenue, reflecting muted investor appetite for defensive chemicals-sector deals.

Share-price reaction clouds merger rationale

As reported by Financial Times, the proposed tie-up between Huntsman and Olin is drawing a negative market response despite management presenting it as a balanced shares-based combination. Huntsman shares fall 17% and Olin shares drop 6% on Tuesday, wiping nearly $650 million from their combined market capitalisation after the announcement.

The deal is positioned as a merger of equals, with both companies arguing that an all-stock structure allows investors to benefit from future gains. That argument is proving difficult to sell because both groups have already endured years of weak share performance, with their stocks down more than 40% over the past five years amid higher input costs, uneven demand and geopolitical disruption.

The companies say the merger should deliver $400 million in annual savings, which they value at roughly $3 billion in aggregate. Even so, investors appear to be questioning whether those synergies can be realised quickly enough to justify the transaction and offset the risks that come with integrating two businesses in cyclical commodity and materials markets.

Chemicals sector pressures shape investor doubts

Part of the challenge for Huntsman and Olin is that their end markets remain essential but lack the growth profile currently favoured by Wall Street. Their combined enterprise value, at $10 billion as of Monday's close, stands below a single year's combined revenue, underscoring how cheaply the market is valuing the pair relative to more highly rated growth companies.

That backdrop leaves little room for error in a defensive merger built on modest premiums and cost-cutting logic. Huntsman investors, in particular, may have preferred a cash offer at a premium rather than stock whose value remains tied to the same industry pressures that have weighed on both companies.

Still, the analysis suggests that if the merged company delivers on its forecasts over time, valuations could recover. For now, the immediate reaction indicates investors remain unconvinced that combining two out-of-favour chemical makers is enough to create value on paper or in practice.

Our earlier coverage of the regulatory review of the proposed Rathbones–Investec merger explained that the tie-up has been slowed by heightened scrutiny over compliance requirements and potential competition impacts in wealth management. We noted that both firms are working through the approvals process, and that the extended timetable reflects tougher oversight of consolidation that can reshape competitive dynamics.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.